CN110251511A - 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 - Google Patents
无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 Download PDFInfo
- Publication number
- CN110251511A CN110251511A CN201910404660.9A CN201910404660A CN110251511A CN 110251511 A CN110251511 A CN 110251511A CN 201910404660 A CN201910404660 A CN 201910404660A CN 110251511 A CN110251511 A CN 110251511A
- Authority
- CN
- China
- Prior art keywords
- deoxy
- activity
- demethyl
- prolyl
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2014-0099210 | 2014-08-01 | ||
| KR1020140099210A KR101694879B1 (ko) | 2014-08-01 | 2014-08-01 | 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도 |
| CN201580041277.1A CN106794169B (zh) | 2014-08-01 | 2015-07-31 | 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580041277.1A Division CN106794169B (zh) | 2014-08-01 | 2015-07-31 | 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110251511A true CN110251511A (zh) | 2019-09-20 |
Family
ID=55217893
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910404660.9A Pending CN110251511A (zh) | 2014-08-01 | 2015-07-31 | 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 |
| CN201580041277.1A Active CN106794169B (zh) | 2014-08-01 | 2015-07-31 | 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580041277.1A Active CN106794169B (zh) | 2014-08-01 | 2015-07-31 | 无免疫抑制活性的维持神经再生活性的fk506衍生物及其用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10226446B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3187183B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6370490B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101694879B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN110251511A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016018117A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101694879B1 (ko) * | 2014-08-01 | 2017-01-12 | 주식회사 인트론바이오테크놀로지 | 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도 |
| CN113939519B (zh) * | 2018-12-11 | 2025-02-14 | 莫尔根生物有限公司 | 促进毛发生长的新化合物及包含它们的组合物 |
| US11449807B2 (en) | 2020-01-31 | 2022-09-20 | Walmart Apollo, Llc | Systems and methods for bootstrapped machine learning algorithm training |
| WO2021256894A1 (ko) * | 2020-06-19 | 2021-12-23 | 서울대학교 산학협력단 | 신경 돌기 생장 및 시냅스 형성 활성을 갖는 신규 prolylfk506 유도체 및 그의 용도 |
| CN118460433B (zh) * | 2024-06-04 | 2026-01-06 | 浙江启臻合成生物技术有限公司 | 生产他克莫司的链霉菌工程菌及其构建方法与应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1997369A (zh) * | 2004-05-12 | 2007-07-11 | 阿尔卡森制药有限公司 | 用于预防和/或治疗与靶向钙调神经磷酸酶有关疾病的阿片样受体拮抗剂化合物的应用 |
| US20090325906A1 (en) * | 2008-06-27 | 2009-12-31 | Wendye Robbins | Methods and compositions for therapeutic treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| MX2009006958A (es) * | 2006-12-28 | 2009-07-09 | Limerick Biopharma Inc | Metodos y composiciones para tratamiento terapeutico. |
| KR101261131B1 (ko) | 2010-08-24 | 2013-05-06 | 이화여자대학교 산학협력단 | 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주 |
| KR101632042B1 (ko) * | 2014-06-30 | 2016-06-21 | 주식회사 인트론바이오테크놀로지 | Fk506 유도체를 함유하는 크립토코쿠스 속 곰팡이 및 칸디다 속 곰팡이에 의한 진균 감염을 치료하기 위한 약제학적 조성물 및 그의 용도 |
| KR101694879B1 (ko) * | 2014-08-01 | 2017-01-12 | 주식회사 인트론바이오테크놀로지 | 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도 |
-
2014
- 2014-08-01 KR KR1020140099210A patent/KR101694879B1/ko active Active
-
2015
- 2015-07-31 WO PCT/KR2015/008031 patent/WO2016018117A1/ko not_active Ceased
- 2015-07-31 JP JP2017526030A patent/JP6370490B2/ja active Active
- 2015-07-31 US US15/500,353 patent/US10226446B2/en active Active
- 2015-07-31 CN CN201910404660.9A patent/CN110251511A/zh active Pending
- 2015-07-31 CN CN201580041277.1A patent/CN106794169B/zh active Active
- 2015-07-31 EP EP15827244.3A patent/EP3187183B1/en active Active
-
2018
- 2018-01-29 JP JP2018012496A patent/JP6851334B2/ja active Active
-
2019
- 2019-01-08 US US16/242,386 patent/US10576060B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1997369A (zh) * | 2004-05-12 | 2007-07-11 | 阿尔卡森制药有限公司 | 用于预防和/或治疗与靶向钙调神经磷酸酶有关疾病的阿片样受体拮抗剂化合物的应用 |
| US20090325906A1 (en) * | 2008-06-27 | 2009-12-31 | Wendye Robbins | Methods and compositions for therapeutic treatment |
Non-Patent Citations (3)
| Title |
|---|
| A SHAFIEE 等: "Chemical and biological characterization of two FK506 analogs produced by targeted gene disruption in Streptomyces sp. MA6548", 《J ANTIBIOT (TOKYO)》 * |
| BRUCE G GOLD: "Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders", 《EXPERT OPINION ON INVESTIGATIONAL DRUGS》 * |
| YEON HEE BAN等: "Characterization of FK506 biosynthetic intermediates involved in post-PKS elaboration", 《J. NAT. PROD.》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3187183A1 (en) | 2017-07-05 |
| JP2017523241A (ja) | 2017-08-17 |
| US10226446B2 (en) | 2019-03-12 |
| WO2016018117A1 (ko) | 2016-02-04 |
| KR101694879B1 (ko) | 2017-01-12 |
| KR20160017267A (ko) | 2016-02-16 |
| EP3187183B1 (en) | 2020-04-08 |
| CN106794169B (zh) | 2020-02-04 |
| US20170216254A1 (en) | 2017-08-03 |
| EP3187183A4 (en) | 2018-03-21 |
| JP6851334B2 (ja) | 2021-03-31 |
| US20190134001A1 (en) | 2019-05-09 |
| JP6370490B2 (ja) | 2018-08-08 |
| US10576060B2 (en) | 2020-03-03 |
| JP2018083843A (ja) | 2018-05-31 |
| CN106794169A (zh) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10576060B2 (en) | FK506 derivative maintaining nerve regeneration activity without immunosuppressive activity, and use thereof | |
| KR101599982B1 (ko) | 노노무라에아 종으로부터의 고리형 펩티드, 그에 대한 생산 프로세스 및 이를 포함하는 마이코박테리아 관련 질병의 치료 혹은 예방을 위한 약학적 조성물 | |
| EP3154534B1 (en) | Small molecule efflux pump inhibitors | |
| Stierle et al. | Caspase-1 and 3 inhibiting drimane sesquiterpenoids from the extremophilic fungus, Penicillium solitum | |
| CN103717222A (zh) | 桥二硫二氧代哌嗪及其在治疗癌症方面的用途 | |
| CN1315863A (zh) | 迷迭香酸及其衍生物用作免疫抑制剂或sh2介导过程的抑制剂 | |
| Goudou et al. | Orbicularisine: a spiro-indolothiazine isolated from gills of the tropical bivalve Codakia orbicularis | |
| KR101261131B1 (ko) | 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주 | |
| Ji et al. | Macrocyclic nonapeptides incorporating uncharacterized amino acids with inhibitory effects on Th17 differentiation | |
| TWI753912B (zh) | 神經病症的治療 | |
| Son et al. | Polyketides and anthranilic acid possessing 6-deoxy-α-L-talopyranose from a Streptomyces Species | |
| Summers et al. | 3-normeridamycin: a potent non-immunosuppressive immunophilin ligand is neuroprotective in dopaminergic neurons | |
| KR102134782B1 (ko) | 신규 화합물 및 이를 포함하는 신경계 질환 치료용 약학적 조성물 | |
| JP6791977B2 (ja) | 骨格筋の肥大剤としてのフロスタン−3オール誘導体 | |
| KR20160067079A (ko) | 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도 | |
| JP2002526540A (ja) | 細胞毒性アルカロイド類(ハリツリン) | |
| CN115916787B (zh) | 具有神经突生长和突触形成活性的新型脯氨酰fk506衍生物及其用途 | |
| JPH0386822A (ja) | 神経細胞変性修復剤 | |
| MX2013013863A (es) | Antibioticos novedosos. | |
| KR20250165858A (ko) | Staphylococcus xylosus로부터 분리한 신규 피라지논 유도체 및 이의 용도 | |
| CN117769601A (zh) | 化合物、其制造方法、抗菌剂和医药品 | |
| CN103374057B (zh) | 一种对甘氨酸转运子具有抑制活性的化合物 | |
| Imae | Studies on inhibitors of tumor-associated enzymes from marine sponges | |
| Han | Natural products studies of the marine cyanobacteria Lyngbya semiplena and Lyngbya majuscula | |
| Marquez | Structure and biosynthesis of marine cyanobacterial natural products: Development and application of new NMR methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190920 |